A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC) Meeting Abstract
| Authors: | Tew, W. P.; Sill, M.; McMeekin, D. S.; Secord, A. A.; Bonebrake, A. J.; Schilder, J.; Stuckey, A.; Rice, L.; Tewari, K. S.; Aghajanian, C. |
| Abstract Title: | A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC) |
| Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2014 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358613203530 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.15_suppl.5546 |
| Notes: | Meeting Abstract: 5546 -- Source: Wos |
